Compare Mesoblast Limited (MESO) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Under Armour Inc Class A — how do they compare? Mesoblast Limited trades at $14.24 (market cap $1.75B), while Under Armour Inc Class A trades at $4.83 (market cap $2.07B). The key difference: Under Armour Inc Class A is the larger of the two by market cap, and Mesoblast Limited is more actively traded (239,027 versus 2,680,141). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Under Armour Inc Class A for 18 Days on average.
| MESO | UA | |
|---|---|---|
Market Cap | $1.75B | $2.07B |
Volume | 239,027 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $7.88 |
52-Week Low | $13.19 | $3.96 |
Typical Hold Time | 15 Days | 18 Days |
Enterprise Value | $1.83B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Under Armour (UA) trades at $4.81, up 2.34% with a bullish technical signal despite mixed fundamentals. The company reported declining revenues ($5.16B in 2025, $4.9B in 2026) and negative net income margins (-9.99%), though recent quarterly earnings showed beats in Q4 2025 and Q2 2026. Analyst sentiment is divided with 39.71% buy ratings, while cash flow trends show significant outflows (-$362M net in 2025).
The outlook remains challenging with revenue declines and profitability concerns, but the stock's low P/S ratio (0.41) may attract value investors. Key risks include sustained negative cash flow, competitive pressures, and execution on turnaround strategies. Near-term performance hinges on Q3 2026 earnings and guidance updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
